{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-012263","form_type":"8-K","ticker":"CSTL","cik":"0001447362","company_name":"CASTLE BIOSCIENCES INC","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.104725+00:00","generated_at":"2026-05-15T23:31:47.036331+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Castle Biosciences FY2025 revenue up 4% to $344M, net loss of $24.2M vs income of $18.2M in 2024","bullets":["FY2025 revenue $344.2M (+4% YoY); excluding discontinued tests growth 34%. Core test reports (DecisionDx-Melanoma, TissueCypher) +37%.","Q4 revenue $87.0M (+1%); core reports +42%. TissueCypher reports up 86% in FY2025.","Net loss $24.2M ($0.83 loss per share) vs net income $18.2M ($0.66 EPS) in 2024. Adj. net loss per share $0.14.","Adjusted EBITDA $44.0M (FY2025) vs $75.0M (2024); net cash from ops $64.3M; cash & securities $299.5M at year-end.","2026 revenue guidance $340-350M; AdvanceAD-Tx limited launch; multiple publications support test utility."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-012263","json":"https://secwatch.observer/filing/0001628280-26-012263.json","markdown":"https://secwatch.observer/filing/0001628280-26-012263.md","text":"https://secwatch.observer/filing/0001628280-26-012263.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447362/000162828026012263/0001628280-26-012263-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447362/000162828026012263/cstl-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:31:47.036331+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}